Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02873156 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT02873156 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 74 participants.
The verdict
NCT02873156, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of multiple ascending oral doses of E2027 in healthy participants.
Interventions
- DRUG E2027
- DRUG E2027 matched placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2016-08-10 |
| Est. Completion | 2017-11-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02873156
The ClinicalTrials.gov registry entry for NCT02873156 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which E2027 is the first listed.
NCT02873156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02873156 about?
NCT02873156 is a clinical study titled "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects". The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of multiple ascending oral doses of E2027 in healthy participants.
What is the current status of trial NCT02873156?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2016-08-10. Estimated completion is 2017-11-29.
What interventions are being tested in trial NCT02873156?
The interventions under investigation include: E2027 (DRUG), E2027 matched placebo (DRUG).
Who is sponsoring clinical trial NCT02873156?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.